Aurobindo Pharma Ltd
Aurobindo Pharma Ltd (AUROPHARMA) last reported results for the quarter ended Jun 2026, with sales of ₹9,150 crore and net profit of ₹1,032 crore. The stock last traded at ₹1,681, a market capitalisation of ₹96,710 crore, on a P/E of 25.6. Over the past 52 weeks the stock has ranged between ₹1,066 and ₹1,740. Figures are as of 6 Oct 2026 and are not real time.
Aurobindo Pharma Ltd share price and key metrics
- Current price
- ₹1,681
- Market cap
- ₹96,710 cr
- Stock P/E
- 25.6
- Book value
- ₹652
- ROE
- 10.1%
- ROCE
- 12.9%
- Dividend yield
- 0.24%
- 52w high / low
- 1740/1066
Metrics as of 6 Oct 2026. Not real time.
Track Aurobindo Pharma Ltd
Cruxal reads every Aurobindo Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Aurobindo Pharma Ltd growth and returns
- 10 Years
- 9%
- 5 Years
- 6%
- 3 Years
- 11%
- TTM
- 9%
- 10 Years
- 6%
- 5 Years
- 1%
- 3 Years
- 23%
- TTM
- 11%
- 10 Years
- 7%
- 5 Years
- 18%
- 3 Years
- 23%
- 1 Year
- 53%
- 10 Years
- 14%
- 5 Years
- 10%
- 3 Years
- 11%
- Last Year
- 10%
Aurobindo Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹9,150 cr, up 16.3% from ₹7,868 cr a year earlier. Net profit was ₹1,032 cr, up 25.2% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 7,796 | 7,979 | 8,382 | 7,868 | 8,286 | 8,646 | 8,853 | 9,150 |
| Expenses | 6,230 | 6,401 | 6,622 | 6,265 | 6,608 | 6,873 | 7,103 | 7,271 |
| Operating profit | 1,566 | 1,578 | 1,760 | 1,603 | 1,678 | 1,773 | 1,750 | 1,880 |
| OPM % | 20% | 20% | 21% | 20% | 20% | 21% | 20% | 21% |
| Other income | 136 | 159 | 135 | 107 | 122 | 123 | 117 | 224 |
| Interest | 113 | 118 | 115 | 98 | 95 | 93 | 98 | 102 |
| Depreciation | 382 | 419 | 444 | 406 | 429 | 465 | 479 | 487 |
| Profit before tax | 1,207 | 1,200 | 1,335 | 1,207 | 1,276 | 1,339 | 1,291 | 1,515 |
| Tax % | 32% | 30% | 32% | 32% | 34% | 32% | 29% | 32% |
| Net profit | 817 | 846 | 903 | 824 | 848 | 910 | 921 | 1,032 |
| EPS (₹) | 14.07 | 14.56 | 15.56 | 14.20 | 14.61 | 15.67 | 15.86 | 17.95 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Aurobindo Pharma Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 14,910 | 16,463 | 19,564 | 23,099 | 24,775 | 23,455 | 24,855 | 29,002 | 31,724 | 33,653 | 34,935 |
| Operating profit | 3,441 | 3,772 | 3,952 | 4,849 | 5,278 | 4,396 | 3,707 | 5,826 | 6,560 | 6,870 | 7,081 |
| OPM % | 23% | 23% | 20% | 21% | 21% | 19% | 15% | 20% | 21% | 20% | 20% |
| Net profit | 2,301 | 2,423 | 2,364 | 2,844 | 5,334 | 2,647 | 1,928 | 3,169 | 3,484 | 3,503 | 3,711 |
| EPS (₹) | 39.29 | 41.36 | 40.36 | 48.56 | 91.05 | 45.20 | 32.90 | 54.15 | 60.02 | 60.34 | 64.09 |
TTM is the trailing twelve months to the most recent quarter.
Aurobindo Pharma Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 58 | 58 |
| Reserves | 9,313 | 11,622 | 13,832 | 16,766 | 21,871 | 24,517 | 26,781 | 29,784 | 32,595 | 37,833 |
| Borrowings | 3,364 | 4,770 | 6,967 | 5,826 | 5,339 | 2,851 | 5,286 | 6,648 | 8,263 | 8,073 |
| Other liabilities | 3,464 | 4,492 | 5,414 | 6,113 | 6,147 | 6,211 | 7,379 | 8,227 | 8,566 | 12,232 |
| Total liabilities | 16,200 | 20,942 | 26,271 | 28,765 | 33,416 | 33,638 | 39,505 | 44,717 | 49,482 | 58,196 |
| Fixed assets | 4,834 | 6,521 | 8,475 | 9,396 | 9,374 | 10,532 | 11,024 | 14,493 | 14,794 | 17,407 |
| CWIP | 1,458 | 1,583 | 1,668 | 1,986 | 3,062 | 3,747 | 5,390 | 3,869 | 4,900 | 5,214 |
| Investments | 246 | 312 | 360 | 555 | 591 | 997 | 543 | 372 | 252 | 1,051 |
| Other assets | 9,662 | 12,527 | 15,768 | 16,827 | 20,390 | 18,362 | 22,549 | 25,983 | 29,536 | 34,525 |
| Total assets | 16,200 | 20,942 | 26,271 | 28,765 | 33,416 | 33,638 | 39,505 | 44,717 | 49,482 | 58,196 |
As reported by the company. Total assets equal total liabilities by construction.
Aurobindo Pharma Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 3,279 | 1,955 | 1,651 | 4,381 | 3,329 | 5,016 | 2,387 | 2,435 | 3,925 | 5,526 |
| Cash from investing | -1,787 | -1,927 | -2,904 | -1,563 | 597 | -3,211 | -3,971 | -4,242 | -1,866 | -2,630 |
| Cash from financing | -1,915 | 864 | 1,919 | -1,947 | -1,365 | -2,969 | 1,814 | 800 | 120 | -1,269 |
| Net cash flow | -424 | 892 | 666 | 871 | 2,561 | -1,164 | 230 | -1,007 | 2,178 | 1,628 |
| Free cash flow | 1,594 | 714 | 114 | 2,969 | 1,503 | 2,693 | -323 | -1,067 | 1,408 | 2,468 |
| CFO / operating profit | 118% | 70% | 61% | 106% | 87% | 143% | 84% | 72% | 86% | 107% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Aurobindo Pharma Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 25% | 23% | 18% | 19% | 18% | 13% | 9% | 14% | 14% | 13% |
| Debtor days | 68 | 68 | 64 | 68 | 52 | 62 | 66 | 61 | 66 | 77 |
| Inventory days | 246 | 317 | 304 | 289 | 333 | 272 | 275 | 284 | 295 | 326 |
| Days payable | 122 | 128 | 107 | 97 | 103 | 97 | 125 | 129 | 117 | 151 |
| Cash conversion cycle | 191 | 257 | 260 | 260 | 282 | 237 | 216 | 216 | 244 | 252 |
| Working capital days | 51 | 50 | 25 | 35 | 52 | 84 | 55 | 66 | 49 | 44 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Aurobindo Pharma Ltd shareholding pattern
Promoters held 51.88% at Jun 2026, broadly unchanged since Jun 2025. FIIs 16.38% and DIIs 25.05%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.88% |
| FIIs | 16.59% | 16.29% | 15.33% | 14.38% | 14.21% | 13.95% | 15.24% | 16.38% |
| DIIs | 25.14% | 25.21% | 26.23% | 26.93% | 27.60% | 27.66% | 25.82% | 25.05% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.03% | 0.05% | 0.05% |
| Public | 6.45% | 6.67% | 6.61% | 6.88% | 6.37% | 6.55% | 7.08% | 6.63% |
| No. of shareholders | 2,48,488 | 2,57,962 | 2,69,323 | 2,72,208 | 2,47,662 | 2,36,859 | 2,41,298 | 2,39,073 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Aurobindo Pharma Ltd corporate filings
- Aurobindo Pharma publishes newspaper notice under Regulation 30 (LODR)Company Updatelow impact
Cruxal's analysis: The company has issued a notice published in newspapers as part of regulatory compliance…
Read the full analysis - Submission of certificate in terms of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.Company Updatelow impact
- Aurobindo Pharma Receives USFDA Final Approval for Perampanel Tablets (2-12 mg)Company Updatelow impact
Cruxal's analysis: Aurobindo Pharma announced the receipt of USFDA final approval for Perampanel Tablets in…
Read the full analysis - Aurobindo Pharma completes acquisition of A1 Biochem Group's Contract Research Services business, gaining access to 50+ clients and 800+ projects, enhancing its integrated CRDMO platform.Company Updatehigh impact
Cruxal's analysis: Aurobindo Pharma has finalized the acquisition of the Contract Research Services business…
Read the full analysis - Aurobindo Pharma completes USD 15.247 million acquisition of A1 Labs LLC, expanding its contract research capabilities in the USCompany Updatehigh impact
Cruxal's analysis: Aurobindo Pharma has announced the acquisition of 100% ownership of A1 Labs LLC, a…
Read the full analysis - Aurobindo Pharma's subsidiary A1 Biochem Labs issues new securities to former promoter, Dr. Rajendra Gadikota, diluting ownership to 20%Company Updatemedium impact
Cruxal's analysis: Aurobindo Pharma Limited disclosed that its step-down subsidiary A1 Biochem Labs has…
Read the full analysis - Aurobindo Pharma launches ADQUEY in the U.S., establishing a dedicated dermatology businessCompany Updatelow impact
Cruxal's analysis: The company announced the submission of a press release regarding the launch of ADQUEY in…
Read the full analysis - Intimation of order passed by Appellate Joint Commissioner (ST), Malkajgiri Division, Hyderabad, Telangana.Company Updatemedium impact
- Intimation of closure of trading window.Insider Trading / SASTlow impact
- Aurobindo Pharma schedules investor and analyst meeting for September 24, 2026Company Updatelow impact
Cruxal's analysis: Aurobindo Pharma has issued an intimation regarding an investor and analyst meeting…
Read the full analysis - Aurobindo Pharma completes US FDA inspection at Apitoria Pharma Unit-IICompany Updatelow impact
Cruxal's analysis: Aurobindo Pharma has announced the completion of a US FDA inspection at Unit-II of its…
Read the full analysis - Aurobindo Pharma receives US FDA final approval for Beclomethasone Dipropionate HFA Inhalation AerosolCompany Updatemedium impact
Cruxal's analysis: Aurobindo Pharma has secured final approval from the US FDA for Beclomethasone…
Read the full analysis - Aurobindo Pharma incorporates US subsidiary 'A1 Biochem USA Inc' for Contract Research and Development servicesCompany Updatelow impact
Cruxal's analysis: Aurobindo Pharma Limited has completed the subscription of 10,000 equity shares in its…
Read the full analysis - Aurobindo Pharma subsidiary Apitoria Pharma completes US FDA inspection at Unit-IVCompany Updatelow impact
Cruxal's analysis: Aurobindo Pharma has announced the completion of a US FDA inspection at Unit-IV of its…
Read the full analysis - Aurobindo Pharma schedules investor and analyst meeting for September 22, 2026Company Updatelow impact
Cruxal's analysis: Aurobindo Pharma has announced an investor and analyst meeting scheduled for September…
Read the full analysis - Aurobindo Pharma schedules investor and analyst meeting for September 21, 2026Company Updatelow impact
Cruxal's analysis: Aurobindo Pharma has announced an intimation for an investor and analyst meeting…
Read the full analysis - Aurobindo Pharma schedules investor and analyst meeting for September 17, 2026Company Updatelow impact
Cruxal's analysis: Aurobindo Pharma has issued a formal intimation regarding an investor and analyst meeting…
Read the full analysis - Aurobindo Pharma schedules investor and analyst meeting for September 18, 2026Company Updatelow impact
Cruxal's analysis: Aurobindo Pharma has issued an intimation regarding an investor and analyst meet…
Read the full analysis - Aurobindo Pharma schedules investor and analyst meeting for September 17, 2026Company Updatelow impact
Cruxal's analysis: Aurobindo Pharma has announced an investor and analyst meeting scheduled to take place on…
Read the full analysis - Aurobindo Pharma Ltd submits newspaper publication notice regarding regulatory complianceCompany Updatelow impact
Cruxal's analysis: Aurobindo Pharma has submitted a notice published in newspapers in accordance with…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.